Harnessing Immune Response in Acute Myeloid Leukemia.
AML
CAR-T
NK cells
immunotherapy
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
07 Sep 2023
07 Sep 2023
Historique:
received:
08
08
2023
revised:
30
08
2023
accepted:
04
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Despite the results achieved with the evolution of conventional chemotherapy and the inclusion of targeted therapies in the treatment of acute myeloid leukemia (AML), survival is still not satisfying, in particular in the setting of relapsed/refractory (R/R) disease or elderly/unfit patients. Among the most innovative therapeutic options, cellular therapy has shown great results in different hematological malignancies such as acute lymphoblastic leukemia and lymphomas, with several products already approved for clinical use. However, despite the great interest in also expanding the application of these new treatments to R/R AML, no product has been approved yet for clinical application. Furthermore, cellular therapy could indeed represent a powerful tool and an appealing alternative to allogeneic hematopoietic stem cell transplantation for ineligible patients. In this review, we aim to provide an overview of the most recent clinical research exploring the effectiveness of cellular therapy in AML, moving from consolidated approaches such as post- transplant donor's lymphocytes infusion, to modern adoptive immunotherapies such as alloreactive NK cell infusions, engineered T and NK cells (CAR-T, CAR-NK) and novel platforms of T and NK cells engaging (i.e., BiTEs, DARTs and ANKET
Identifiants
pubmed: 37762763
pii: jcm12185824
doi: 10.3390/jcm12185824
pmc: PMC10532363
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Curr Hematol Malig Rep. 2017 Dec;12(6):547-556
pubmed: 29027628
Front Immunol. 2018 Feb 15;9:227
pubmed: 29497419
Nat Rev Drug Discov. 2019 Aug;18(8):585-608
pubmed: 31175342
Leukemia. 2000 Oct;14(10):1777-84
pubmed: 11021753
J Hematol Oncol. 2020 Nov 19;13(1):155
pubmed: 33213500
Br J Haematol. 2019 Mar;184(5):782-787
pubmed: 30467839
Blood. 2012 Apr 5;119(14):3256-62
pubmed: 22337715
Blood. 2011 Apr 28;117(17):4403-4
pubmed: 21527536
Blood. 2022 Sep 22;140(12):1345-1377
pubmed: 35797463
Br J Haematol. 2008 Dec;143(5):641-53
pubmed: 18950462
Oncoimmunology. 2014 Mar 17;3:e28187
pubmed: 25340010
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Cytometry B Clin Cytom. 2019 Mar;96(2):134-142
pubmed: 30450744
Haematologica. 2019 Jan;104(1):113-119
pubmed: 30076173
Haematologica. 2018 Aug;103(8):1390-1402
pubmed: 29700172
Bone Marrow Transplant. 2016 Nov;51(11):1431-1438
pubmed: 27295272
Blood. 2011 Jan 20;117(3):764-71
pubmed: 20889923
Clin Pharmacokinet. 2016 Oct;55(10):1271-1288
pubmed: 27209293
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Blood. 2000 Jan 1;95(1):67-71
pubmed: 10607686
Cell. 2018 Dec 13;175(7):1731-1743.e13
pubmed: 30503213
Front Oncol. 2021 Apr 15;11:671252
pubmed: 33937085
Blood. 2009 Mar 26;113(13):3119-29
pubmed: 18945967
J Immunother. 2007 Nov-Dec;30(8):798-807
pubmed: 18049331
Blood. 2003 Aug 1;102(3):814-9
pubmed: 12689936
Blood. 2013 Jul 4;122(1):83-92
pubmed: 23656730
Cancers (Basel). 2022 Feb 27;14(5):
pubmed: 35267549
Nat Biotechnol. 2023 Sep;41(9):1296-1306
pubmed: 36635380
Haematologica. 2016 May;101(5):626-33
pubmed: 26721894
Int J Cancer. 2002 Aug 20;100(6):690-7
pubmed: 12209608
J Clin Oncol. 2011 Feb 1;29(4):369-77
pubmed: 21172891
Front Oncol. 2022 Feb 17;12:841608
pubmed: 35252010
Clin Cancer Res. 2016 Apr 15;22(8):1914-21
pubmed: 26787753
Nat Rev Cancer. 2021 Mar;21(3):145-161
pubmed: 33483715
Mol Cancer Ther. 2012 Dec;11(12):2674-84
pubmed: 23075808
Cancers (Basel). 2020 Oct 23;12(11):
pubmed: 33113953
Bone Marrow Transplant. 2022 Jan;57(1):116-118
pubmed: 34611291
Blood Cancer J. 2022 Apr 13;12(4):61
pubmed: 35418180
Physiol Rev. 2019 Jul 1;99(3):1433-1466
pubmed: 31066629
Strahlenther Onkol. 2017 Feb;193(2):95-99
pubmed: 27704149
Cell. 2001 Jun 29;105(7):913-23
pubmed: 11439187
Ther Adv Hematol. 2018 Jun;9(6):135-148
pubmed: 29899889
Annu Rev Immunol. 2023 Apr 26;41:17-38
pubmed: 36446137
Cancers (Basel). 2021 Oct 22;13(21):
pubmed: 34771483
J Clin Med. 2019 Feb 06;8(2):
pubmed: 30736352
Cancer. 2019 May 1;125(9):1470-1481
pubmed: 30500073
Semin Immunol. 2019 Feb;41:101272
pubmed: 31085114
Acta Haematol. 2017;138(3):175-181
pubmed: 29065396
Nature. 1985 Apr 18-24;314(6012):628-31
pubmed: 2859527
Science. 2002 Mar 15;295(5562):2097-100
pubmed: 11896281
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Leukemia. 2021 Jul;35(7):1843-1863
pubmed: 33953290
Clin Cancer Res. 2013 Jul 15;19(14):3844-55
pubmed: 23690482
Cancer Discov. 2019 Mar;9(3):370-383
pubmed: 30409776
Annu Rev Pharmacol Toxicol. 2015;55:489-511
pubmed: 25562645
Nature. 1985 Jul 25-31;316(6026):354-6
pubmed: 3160953
Clin Cancer Res. 2016 Dec 1;22(23):5829-5838
pubmed: 27189165
Blood. 2008 Dec 1;112(12):4371-83
pubmed: 19029455
Drug Discov Today. 2008 Aug;13(15-16):695-701
pubmed: 18621567
J Clin Oncol. 2012 Nov 10;30(32):3924-31
pubmed: 22851554
Biol Blood Marrow Transplant. 2018 Jul;24(7):1350-1359
pubmed: 29649617
Cytotherapy. 2006;8(6):554-8
pubmed: 17148031
Blood. 1999 Jul 15;94(2):434-41
pubmed: 10397710
Clin Transl Immunology. 2021 Apr 28;10(4):e1274
pubmed: 33959279
Biol Blood Marrow Transplant. 2010 Dec;16(12):1728-37
pubmed: 20542125
J Hematol Oncol. 2019 Apr 24;12(1):41
pubmed: 31014360
J Clin Invest. 2020 Apr 1;130(4):1552-1564
pubmed: 32235097
Front Immunol. 2019 Dec 06;10:2836
pubmed: 31867006
Blood. 2000 Jul 15;96(2):483-90
pubmed: 10887109
Blood. 1993 Oct 15;82(8):2310-8
pubmed: 8400284
Blood. 2007 Jun 1;109(11):5063-4
pubmed: 17522340
Clin Exp Immunol. 2009 Sep;157(3):325-31
pubmed: 19664139
J Clin Oncol. 2010 Feb 20;28(6):955-9
pubmed: 20085940
Blood. 2014 Sep 18;124(12):1880-6
pubmed: 25082877
Front Oncol. 2021 Jun 10;11:673276
pubmed: 34178661
Transfusion. 2014 Jun;54(6):1493-500
pubmed: 24372162
Int J Mol Sci. 2022 Dec 14;23(24):
pubmed: 36555547
Mol Immunol. 2006 Feb;43(6):763-71
pubmed: 16360021
J Exp Med. 1988 Feb 1;167(2):452-72
pubmed: 2831292
Eur J Haematol. 2014 Sep;93(3):239-46
pubmed: 24702162
Front Oncol. 2019 Nov 19;9:1217
pubmed: 31803612
Immunotherapy. 2010 Jan;2(1):85-97
pubmed: 20635891
J Hematol Oncol. 2022 Jul 7;15(1):88
pubmed: 35799191
J Leukoc Biol. 2011 Oct;90(4):661-7
pubmed: 21791599
Blood. 1990 Dec 15;76(12):2462-5
pubmed: 2265242
Blood. 2005 Apr 15;105(8):3051-7
pubmed: 15632206
Blood Cancer J. 2021 Feb 22;11(2):41
pubmed: 33619261
Haematologica. 2014 Aug;99(8):1277-84
pubmed: 25082785
Blood. 2011 Sep 22;118(12):3273-9
pubmed: 21791425
Blood. 2002 Oct 15;100(8):2980-8
pubmed: 12351411
Clin Transl Sci. 2023 Mar;16(3):429-435
pubmed: 36564917
Haematologica. 2023 Jul 01;108(7):1793-1802
pubmed: 36779592
Blood. 2014 Feb 27;123(9):1412-21
pubmed: 24357730
Biomark Res. 2022 Mar 18;10(1):12
pubmed: 35303962
Aging Dis. 2020 Feb 1;11(1):118-128
pubmed: 32010486
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258
Cancers (Basel). 2021 Aug 15;13(16):
pubmed: 34439266